FDA Approves Opdivo Qvantig for Mesothelioma
FDA approval of Opdivo Qvantig allows subcutaneous nivolumab delivery in under 5 minutes, compared to 30-minute IV infusions for people with mesothelioma.
The FDA approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) on December 27, 2024, a subcutaneous formulation that delivers the same immunotherapy in under 5 minutes compared to the 30-minute intravenous infusion previously required. This approval includes the mesothelioma indication where nivolumab is used in combination with ipilimumab as first-line treatment.
For people with mesothelioma who may receive nivolumab every 2-4 weeks for extended periods, the time savings and convenience of subcutaneous administration represents a meaningful improvement in treatment experience.
What Changed with This Approval
Administration method: Opdivo Qvantig is injected subcutaneously (under the skin) rather than infused intravenously. The injection takes approximately 3-5 minutes compared to 30 minutes for the IV formulation.
Same active drug: The nivolumab molecule is identical to IV Opdivo. The subcutaneous formulation adds hyaluronidase, an enzyme that helps the drug absorb into the bloodstream from under the skin.
Same dosing schedule: Patients receive Opdivo Qvantig on the same schedule as IV nivolumab, either every 2 weeks (240 mg) or every 4 weeks (480 mg).
Same efficacy: Clinical trials demonstrated equivalent drug exposure and efficacy between subcutaneous and IV formulations.
Clinical Trial Data
The approval was based on the CheckMate-8LX study (NCT05220982), which compared pharmacokinetics and safety between subcutaneous and IV nivolumab:
Pharmacokinetic equivalence: The study demonstrated that subcutaneous nivolumab achieved equivalent blood levels to IV nivolumab across multiple tumor types.
Safety profile: Adverse events were similar between formulations. Injection site reactions occurred in some patients receiving subcutaneous administration, typically mild and manageable.
Patient preference: Studies of subcutaneous immunotherapy formulations generally show patient preference for shorter administration times and the option for less frequent clinic visits.
Implications for people with mesothelioma
The nivolumab plus ipilimumab combination (CheckMate 743) is approved as first-line treatment for unresectable pleural mesothelioma. Under this regimen:
- Nivolumab: 360 mg every 3 weeks or 3 mg/kg every 2 weeks
- Ipilimumab: 1 mg/kg every 6 weeks
- Treatment continues until disease progression or unacceptable toxicity
With the Opdivo Qvantig approval, the nivolumab portion of this regimen can now be delivered subcutaneously. This means:
Shorter infusion visits: Overall chair time decreases significantly when nivolumab is given subcutaneously. Ipilimumab still requires IV infusion on its scheduled days.
Potential for home administration: While not yet standard practice, subcutaneous formulations open possibilities for future home-based administration under appropriate supervision.
Reduced burden: For patients traveling long distances to treatment centers, shorter visits reduce fatigue and time away from home.
How Subcutaneous Immunotherapy Works
Hyaluronidase, the added enzyme in Opdivo Qvantig, temporarily breaks down hyaluronan in the tissue under the skin. This allows larger volumes of medication to be absorbed more quickly than would otherwise be possible with subcutaneous injection.
This technology has been used successfully in other cancer treatments, including subcutaneous formulations of rituximab (Rituxan Hycela) and trastuzumab (Herceptin Hylecta), which have been available for several years.
What This Means Practically
Ask your oncologist: If you are currently receiving IV nivolumab or will be starting nivolumab-based treatment, discuss whether Opdivo Qvantig is appropriate for your situation.
Insurance coverage: New formulations may require prior authorization. Your treatment team can help navigate coverage questions.
Same monitoring: Subcutaneous administration does not change the need for regular monitoring of treatment response and side effects.
Combination treatment: When receiving nivolumab plus ipilimumab, you will still need IV access for ipilimumab infusions.
If you’re currently receiving IV nivolumab or starting nivolumab-based treatment, ask whether Opdivo Qvantig is appropriate for your situation. Insurance coverage may require prior authorization. Your treatment team can help navigate this.
The Broader Trend
The Opdivo Qvantig approval reflects a broader movement toward more convenient immunotherapy delivery:
Patient-centered care: Reducing treatment burden without sacrificing efficacy improves quality of life during cancer treatment.
Healthcare efficiency: Shorter administration times free up infusion center capacity and reduce healthcare costs.
Future developments: Other immunotherapy agents may follow with subcutaneous formulations as manufacturers seek to improve patient experience.
Current Availability
Opdivo Qvantig became available in the United States following the December 2024 approval. Patients interested in transitioning from IV to subcutaneous nivolumab should discuss timing and logistics with their oncology team.
The approval covers all adult indications previously approved for IV Opdivo, including unresectable malignant pleural mesothelioma in combination with ipilimumab.
Related Articles
Reader Q&A
Frequently Asked Questions
What is Opdivo Qvantig?
Opdivo Qvantig is a subcutaneous formulation of nivolumab (with hyaluronidase) that delivers the same immunotherapy in under 5 minutes compared to the 30-minute IV infusion previously required. It contains the identical nivolumab molecule with equivalent efficacy.
Does this affect mesothelioma treatment?
Yes. The nivolumab plus ipilimumab combination is approved as first-line treatment for unresectable pleural mesothelioma. With Opdivo Qvantig, the nivolumab portion can now be delivered subcutaneously, significantly reducing chair time. Ipilimumab still requires IV infusion.
How does subcutaneous delivery work?
Hyaluronidase, an enzyme added to the formulation, temporarily breaks down hyaluronan in tissue under the skin. This allows larger volumes of medication to absorb more quickly than would otherwise be possible with subcutaneous injection.
Is the subcutaneous version as effective as IV?
Yes. Clinical trials (CheckMate-8LX) demonstrated that subcutaneous nivolumab achieved equivalent blood levels and efficacy to IV nivolumab. The safety profile was similar, with mild, manageable injection site reactions in some patients.
What is the life expectancy of someone with immunotherapy for mesothelioma?
People with mesothelioma treated with immunotherapy, such as Opdivo plus Yervoy, have a median survival of 18.1 months, compared to 14.1 months with chemotherapy alone, per the CheckMate 743 trial. Keytruda combined with chemotherapy yields a median survival of 17.3-19.8 months. The DREAM trial reported 20.4 months median overall survival with durvalumab plus chemotherapy, rising to 24.3 months for epithelioid pleural mesothelioma. Overall, 3-year survival rates reach 23-25% with these treatments.
How did Steve McQueen get mesothelioma?
Steve McQueen was exposed to asbestos through multiple occupational and military sources over several decades. His primary exposure occurred during his service in the U.S. Marine Corps from 1947 to 1950, when he worked aboard naval ships and in shipyards, including removing asbestos lagging from pipes at Camp Lejeune. After his military service, he encountered additional asbestos exposure on movie soundstages where insulation contained the mineral, while wearing flame-resistant racing suits made with asbestos, and while working on race car and motorcycle brakes. McQueen did not develop symptoms until 1978, nearly 30 years after his initial military exposure, reflecting the typical latency period of 20 to 50 years between asbestos exposure and mesothelioma diagnosis. He was diagnosed with pleural mesothelioma in December 1979 and died in November 1980 at age 50.
How long can Opdivo extend life?
Opdivo combined with Yervoy showed a median overall survival of 72.1 months in people with advanced melanoma, compared to 36.9 months with Opdivo alone and 19.9 months with Yervoy alone, in a phase 3 trial with 6.5-year follow-up. Ten-year data from the same trial indicated 52% survival excluding non-melanoma deaths with the combination. In advanced non-small cell lung cancer, Opdivo alone achieved a 16% five-year survival rate in a phase 1 trial, exceeding historical rates of about 5% [6,8]. No phase 3 trial data specifically for people with mesothelioma were identified. Opdivo remains detectable in the body for 3-4 months post-dose, with risks potentially lasting longer.
What is the best immunotherapy for mesothelioma?
FDA-approved immunotherapies for unresectable pleural mesothelioma include nivolumab (Opdivo) plus ipilimumab (Yervoy), with median overall survival of 18.1 months versus 12-14 months for chemotherapy alone in the CheckMate 743 trial, and pembrolizumab (Keytruda) plus pemetrexed and platinum chemotherapy, with approximately 18 months median survival in the KEYNOTE-483 trial. The Opdivo-Yervoy combination shows particular effectiveness for people with non-epithelioid (sarcomatoid or biphasic) mesothelioma, nearly doubling survival compared to chemotherapy. The DREAM trial reported 20.4 months median overall survival with durvalumab plus chemotherapy, higher for epithelioid subtypes at 24.3 months. No single immunotherapy is designated as best across all cases, as outcomes vary by histology and trial data.